Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't madder they will short it till it gets delisted then we will have to do a RS
Pretty much, very interesting pipeline. I think you will see more institutional buying moving forward. Patience with this gem $$$$
Lol probably I bought options 400 even price $1.04
Someday in the next 10 years I guess
Someday just not today
Good news all around.
mb
We’l see, let er rip north
OCGN chart reversal has begun.
mb
More mojo added here, moving forward $$$$
I think you own this board and pretty much talking to yourself
Many bagholders waiting hopelessly at this time
514,209 buy order right after close
The covid vaccine is top notch in india an saving lives, this would be huge
Don't see it happen
MY be the retina cure will be the better bet than vaccine
Why would that be?
Shorts may get crushed here, soon $$$$
Sure is, patience! $$$$
Still holding. 8k today. New deck. The pipeline is real af. https://ocugen.gcs-web.com/static-files/7aab3ebd-17cb-42be-8e99-791a87709c83
Lol told ya!our own government stealing from us
Shorts going to drop a bomb rite out the gate to get everyone that bought premarket to hit stop loss
Don't worry they will short it till we close in red like usual
Insiders are loading now. Hhhmmmm, could very positive news be on the horizon here
.25 coming then the big RS, thats what happens when scum an thieves run a company! Lmao
Maybe some good science coming here folks. $$$
Yep been awhile my friend
Long time no see.
Is it a buy now? I lost on this crap on the fda rejection for the vaccine approval.
Dumped, in an out! Quick money. This company is on pins an needles, only good for flippn
We loaded up this little bio could pop to 3.50/4.00, patience an sit back on them
After hours great news yesterday!!!
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
Source: GlobeNewswire Inc.?
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Independent Data and Safety Monitoring Board (DSMB) for the OCU400 Phase 1/2 clinical trial completed a review of safety data for subjects enrolled in Cohort 2 and recommends proceeding to enroll subjects in Cohort 3. The Company expects to complete Cohort 3 enrollment in Q4 2022 as planned.
“I’m very pleased with the progress of the clinical trial,” said David Birch, PhD, Director, Retina Foundation of the Southwest, primary investigator of the study. “Currently, patients with inherited retinal degeneration have nothing to address their condition in the long-term. It is imperative to keep working toward a solution for these patients who currently have no hope.”
OCU400 clinical trial is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated with NR2E3 (Nuclear Receptor Subfamily 2 Group E Member 3) and RHO (Rhodopsin) Mutations. OCU400 is part of Ocugen’s Modifier Gene Therapy Platform—targeting inherited retinal disease and dry age-related macular degeneration.
Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN)
Source: TipRanks
Mizuho Securities analyst Uy Ear maintained a Buy rating on Ocugen (OCGN - Research Report) today and set a price target of $5.00. The company's shares closed yesterday at $1.64.Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Ocugen. According to TipRanks, Ear has an average return of -10.4% and a 27.27% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocugen with a $6.33 average price target, which is a 285.98% upside from current levels.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-ocugen-ocgn?utm_source=advfn.com&utm_medium=referral
Bbv152 looks promising folks. Just never know
$30 options open for January
OCGN
Been loading the 2.30’s an flipping the 2.80’s, good wealth on these lines
If the shorts pound this down to the 2 area i would expect a huge volume spike to 2.50’s again, lets c where they take it. The flip has been the 2.50’s to the 2.80’s on a large level but with the recent 8k an news, it’s probable new trading ranges develope since nothing real positive came out here
It still could I’m just stating facts about their recent press release on available funds. These types of stocks are very sketchy/risky. So, I’m both ways on this one.
Followers
|
226
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5672
|
Created
|
11/13/15
|
Type
|
Free
|
Moderators sgunderbarth |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |